Novo Nordisk links CagriSema to 16% weight loss, sending stock down again
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. Three months after missing that target in its first phase 3 CagriSema trial,
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare ...
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
H.C. Wainwright says Novo Nordisk’s REDEFINE-2 results reinforce Viking Therapeutics’ VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema a ...
Novo Nordisk said it will offer all doses of Wegovy for $499 a month to patients paying cash, a bid to reach consumers who ...
Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback